New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
- Dezima Pharma
- Gooimeer 2 - 35
- DC Naarden , 1411
Dezima Pharma develops drugs to treat dyslipidemia, a major modifiable risk for cardiovascular disease. Its objective is to develop compounds from pre-clinical development to meaningful proof of concept in patients. Dezima will seek strategic partners to further development in the larger cardiovascular indications, and/or continue in-house development of its compounds in smaller, orphan-type indications. The Netherlands-based company was founded by Forbion Capital Partner and BioGeneration Ventures.